EMA Sets Up COVID-19 Task Force
The task force will assist in the developing, authorizing, and monitoring of treatments of COVID-19.
To assist member states of the European Union in developing, authorizing, and monitoring treatments of COVID-19, the European Medicines Agency (EMA) has set up the COVID-19 EMA Pandemic Task Force (COVID-ETF). The task force is accountable to EMA’s Committee for Medicinal Products for Human Use (CHMP) and will include CHMP rapporteurs and co-rapporteurs and any additional experts that may be needed, the agency announced in a April 9, 2020 press release.
The COVID-ETF will review available scientific data on possible COVID-19 treatments as well as request data from developers. The task force will also offer scientific support to facilitate clinical trials of COVID-19 treatments and provide feedback on development plans. It will advise the Scientific Advice Working Party or CHMP on formal scientific advice and product-related assessment and contribute to Pharmacovigilance Risk Assessment Committee activities. It will also ensure cooperation with stakeholders and European and international organizations.
Source: EMA
Benuvia Granted GMP Certification by Brazil National Health Surveillance Agency
March 14th 2025The certification allows Benuvia to produce pharmaceutical products for companies, either local to Brazil or international, that may be looking for compliant and high-quality production capabilities in the Brazilian pharmaceutical market.
